pharmacist holding Narcan nasal spray

Company Overview

Opiant Pharmaceuticals, formerly known as Lightlake Therapeutics, was founded in 2009 based on pioneering research demonstrating that opioid antagonists could be used as a symptom-driven treatment for alcohol use disorder. The company began with a Phase 2 study in Binge Eating Disorder (BED) using nasal naloxone in November of 2009 and presented positive results at the American Psychiatric Association (“APA”) Annual Meeting in San Francisco in May of 2013.

However, in response to the opioid overdose epidemic, Opiant refocused its efforts in 2013 to develop the first FDA-approved, user-friendly nasal naloxone spray. In 2015 this product, NARCAN® Nasal Spray 4mg, became available in the United States and Canada through our commercial partner, Adapt Pharma (now a part of Emergent BioSolutions).

Narcan Nasal Spray

Mission, Vision, and Values

In addition to NARCAN® Nasal Spray, we are developing medicines for addictions and drug overdose.

Our clinical pipeline includes a nalmefene nasal spray to better address fentanyl-related opioid overdoses.

We are also initiating Phase 2 studies for OPNT002, nasal naltrexone for Alcohol Use Disorder.

We are further working to advance three preclinical programs.  At the end of 2018, we in-licensed drinabant, a CB-1 antagonist, from Sanofi for Acute Cannabinoid Overdose, a growing issue that directly correlates with increased cannabis legalization, especially for recreational use.

needle icon

We also in-licensed a novel heroin vaccine, developed by the Walter Reed Army Institute of Research (WRAIR) in collaboration with the National Institute on Drug Abuse (NIDA), a division of the National Institute of Health (NIH).

pills icon

We are also exploring a long-lasting opioid antagonist implant for the treatment of Opioid Use Disorder.

Company Evolution Timeline

  1. 2009

    2009 – 2012

    • Changed name from Madrona Ventures to Lightlake Therapeutics
    • Focused on the treatment of Binge Eating Disorder
  2. 2013

    2013 – 2014

    • Entered into a collaboration with NIDA to develop intranasal naloxone for reversal of opioid overdose
    • Executed a global licensing agreement with Adapt Pharma in exchange for development and sales milestones plus royalties
    • Established a research license with Aegis Therapeutics for its proprietary delivery enhancement agent, Intravail®
  3. 2015

    2015 – 2017

    • NARCAN® Nasal Spray approved by the FDA
    • Changed name from Lightlake Therapeutics to Opiant Pharmaceuticals
    • Licensed heroin vaccine from Walter Reed for Opioid Use Disorder
    • Initiated OPNT001 Phase 2 study in Bulimia Nervosa
    • Uplisted to NASDAQ
  4. 2018

    2018 – Present

    • Announced Nasal Nalmefene program with positive Phase 1 data for OPNT003, a long-acting opioid antagonist for opioid overdose
    • Expanded into Acute Cannabinoid Overdose through an exclusive global licensing agreement with Sanofi for OPNT004 (drinabant)